PARP1 and Alzheimer disease: Furthermore, PARP-1 inhibition using nicotinamide or PJ34, which have now been established as weak inhibitors [100], in transgenic mouse models of Alzheimer’s disease ameliorates brain pathology through a reduction of β-amyloid production [101] (Table 3).